Future of CGB, page-12

CGB has/had the Canntab local manufacturing and distribution rights for the Australasian/Asian region.
DFM were meant to fund the upgrade to Biohealths facility so it was capable of manufacturing Canntabs product locally. They now appear to be on their way to being delisted so it seems that manufacturing is a non starter. I suppose the question is the agreement was valid with those two factors in play, is it still valid now that the manufacturing proponent appears void. Perhaps Neil can shed some light on this. The thing with CGB and QBL for that matter is they're good at releasing announcements that appear positive but when things don't eventuate or negative events happen very little is said. I really hope for all holders sake that Canntab is a starter and is adopted by health professionals Australia wide.